Following young people with sleep apnea who receive the Inspire nerve stimulation implant
Follows young people with obstructive sleep apnea for 5 years after an Inspire implant.
Key facts
- Who runs it
- Inspire Medical Systems, Inc.
- Where
- Atlanta, Aurora, Cincinnati, Dallas, Durham, Norfolk, Philadelphia, and Sewickley, United StatesSee the 8 sites
- Trial code
- Registry title
- Pediatric Post-Approval Registry
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 30 Nov 2021
- Expected to end
- Apr 2028
- Type of study
- Observational
- Treatments tested
- Inspire Upper Airway Stimulation System
- Record updated
- 25 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 18 to 21 with moderate to severe obstructive sleep apnea who are getting the Inspire Upper Airway Stimulation System implanted. People are followed for 5 years after the implant.
- Age
- 18 to 21 years
- Sex
- All sexes
- Disease stage
- Moderate to severe obstructive sleep apnea (15 ≤ AHI ≤ 65) on a recent sleep study. AHI counts breathing pauses per hour of sleep.
- Earlier treatment
- Positive airway pressure treatment (such as CPAP) did not work or could not be tolerated, despite efforts to use it. Removal of tonsils and adenoids (adenotonsillectomy) is not possible or did not work. Other alternative or add-on therapies must have been considered.
Main reasons for not taking part
- Central plus mixed apneas make up more than 25% of the total AHI
- Airway anatomy that would stop the stimulation from working, such as complete concentric collapse of the soft palate
- A condition or procedure that has harmed nerve control of the upper airway
- Pregnant or planning to become pregnant
- An implanted device that may interact with the Inspire System, or a terminal illness with life expectancy < 12 months
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Subject is between 18 and 21 years of age
- Subject has a diagnosis of moderate to severe OSA (15 ≤ AHI ≤ 65) based on a recent sleep study
- Subject has documented failure of, or intolerance to, positive airway pressure treatments, despite attempts to improve compliance
- Subject is contraindicated for, or not effectively treated by, adenotonsillectomy
- Subject has followed standard of care in considering all other alternative/adjunct therapies
- Subject is willing and able to have stimulation hardware permanently implanted and to use the patient remote to activate the stimulation
- Subject is willing and able to return for follow-up visits, undergo sleep studies (including in-lab and at-home), and complete questionnaires related to the registry
- Subject is willing and able to provide informed consent
Who cannot take part
- Subject has any condition or procedure that has compromised neurological control of the upper airway
- Subject has a terminal illness with life expectancy < 12 months
- Subject has a combination of central + mixed apneas > 25% of the total apnea-hypopnea index (AHI)
- Subject has any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate
- Subject is unable, or does not have the necessary assistance, to operate the patient remote
- Subject is pregnant or plans to become pregnant
- Subject has an implantable device that may be susceptible to unintended interaction with the Inspire System
- Any other reason the investigator deems the subject is unfit for participation in the registry
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 21 years old?
Where in United States
- Children's Healthcare of AtlantaAtlanta, United StatesContact: Gwen GimmestadNo longer taking part
- Childrens Hospital of ColoradoAurora, United StatesContact: Kari GoreckiTaking people
- Cincinnati Childrens HospitalCincinnati, United StatesContact: Angie DugginsTaking people
- University of Texas Southwestern/Children's Hospital of DallasDallas, United StatesContact: Francesca ChambersTaking people
- Duke UniversityDurham, United StatesContact: Donald LuckettTaking people
- Children's Hospital of the King's Daughters/East Virginia Medical SchoolNorfolk, United StatesContact: Lakshya EnuguTaking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Ashley WilliamsTaking people
- Children's Hospital of PittsburghSewickley, United StatesContact: Amber ShafferTaking people
About the trial
What the trial wants to find out
This registry is a prospective, multi-center, single-arm study of pediatric subjects (ages 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation (UAS) System for the treatment of moderate or severe obstructive sleep apnea (OSA). Implanted subjects will be followed for 5 years post-implant.
The group in the trial
- Registry Population
Pediatric subjects (age 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation System for the treatment of moderate to severe obstructive sleep apnea (OSA)
Treatment: Inspire Upper Airway Stimulation System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Inspire Pediatric Post-Approval Registry
- Plain-language title
- Following young people with sleep apnea who receive the Inspire nerve stimulation implantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT04457154, who can take part
- Record updated
- 25 February 2025